Q3 EPS Estimate for ACADIA Pharmaceuticals Cut by Analyst

Key Points

• The Q3 2025 earnings per share (EPS) estimate for ACADIA Pharmaceuticals has been reduced from $0.15 to $0.14 by analysts at Leerink Partners.
• ACADIA Pharmaceuticals has received mixed ratings from analysts, with a consensus rating of Moderate Buy and a target price of $29.12.
• Insider trading activity includes sales by executive vice president Mark C. Schneyer and director Elizabeth A. Garofalo, signaling a potential shift in confidence among company executives.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at Leerink Partnrs reduced their Q3 2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a report released on Monday, October 6th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will earn $0.14 per share for the quarter, down from their previous forecast of $0.15. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share.

ACAD has been the subject of a number of other research reports. The Goldman Sachs Group upped their price objective on shares of ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the stock a "sell" rating in a research report on Thursday, August 7th. Cowen reiterated a "buy" rating on shares of ACADIA Pharmaceuticals in a report on Thursday, September 11th. Royal Bank Of Canada increased their target price on shares of ACADIA Pharmaceuticals from $39.00 to $40.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Wall Street Zen downgraded shares of ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, September 5th. Finally, TD Cowen lifted their price objective on ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the stock a "buy" rating in a research report on Thursday, September 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $29.12.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock opened at $21.54 on Wednesday. The company has a market cap of $3.63 billion, a P/E ratio of 16.20, a PEG ratio of 7.60 and a beta of 0.75. ACADIA Pharmaceuticals has a one year low of $13.40 and a one year high of $26.65. The firm has a fifty day moving average of $24.12 and a two-hundred day moving average of $20.91.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.14 by $0.02. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The business had revenue of $264.57 million during the quarter, compared to analysts' expectations of $263.07 million. During the same quarter in the prior year, the business earned $0.20 earnings per share. The company's quarterly revenue was up 9.4% compared to the same quarter last year.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its holdings in shares of ACADIA Pharmaceuticals by 645.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 310,332 shares of the biopharmaceutical company's stock valued at $5,065,000 after purchasing an additional 268,714 shares in the last quarter. Comerica Bank increased its position in shares of ACADIA Pharmaceuticals by 4,770.1% during the first quarter. Comerica Bank now owns 43,100 shares of the biopharmaceutical company's stock valued at $716,000 after purchasing an additional 42,215 shares during the period. GAMMA Investing LLC grew its stake in shares of ACADIA Pharmaceuticals by 627.3% in the 1st quarter. GAMMA Investing LLC now owns 3,513 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 3,030 shares during the period. Rhumbline Advisers grew its holdings in shares of ACADIA Pharmaceuticals by 100.9% in the 1st quarter. Rhumbline Advisers now owns 352,716 shares of the biopharmaceutical company's stock worth $5,859,000 after purchasing an additional 177,188 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new stake in ACADIA Pharmaceuticals during the first quarter worth about $247,000. Hedge funds and other institutional investors own 96.71% of the company's stock.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,498 shares of the firm's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $23.65, for a total transaction of $82,727.70. Following the completion of the transaction, the executive vice president directly owned 43,447 shares of the company's stock, valued at $1,027,521.55. This trade represents a 7.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elizabeth A. Garofalo sold 1,600 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $25.98, for a total transaction of $41,568.00. Following the completion of the transaction, the director directly owned 25,382 shares of the company's stock, valued at approximately $659,424.36. This represents a 5.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,098 shares of company stock valued at $678,256 in the last three months. Corporate insiders own 28.30% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.